These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19935379)

  • 1. BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection.
    Zarkhin V; Li L; Sarwal MM
    Transplantation; 2009 Nov; 88(10):1229-30. PubMed ID: 19935379
    [No Abstract]   [Full Text] [Related]  

  • 2. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.
    Thaunat O; Patey N; Gautreau C; Lechaton S; Fremeaux-Bacchi V; Dieu-Nosjean MC; Cassuto-Viguier E; Legendre C; Delahousse M; Lang P; Michel JB; Nicoletti A
    Transplantation; 2008 Jun; 85(11):1648-53. PubMed ID: 18551073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.
    Alausa M; Almagro U; Siddiqi N; Zuiderweg R; Medipalli R; Hariharan S
    Clin Transplant; 2005 Feb; 19(1):137-40. PubMed ID: 15659147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose rituximab as induction in renal transplantation.
    van den Hoogen MW; Hilbrands LB
    Transplantation; 2010 May; 89(10):1295; author reply 1295. PubMed ID: 20555227
    [No Abstract]   [Full Text] [Related]  

  • 5. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
    Pers JO; Devauchelle V; Daridon C; Bendaoud B; Le Berre R; Bordron A; Hutin P; Renaudineau Y; Dueymes M; Loisel S; Berthou C; Saraux A; Youinou P
    Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic evaluation of B-cell subsets after rituximab for treatment of acute renal allograft rejection in pediatric recipients.
    Zarkhin V; Lovelace PA; Li L; Hsieh SC; Sarwal MM
    Transplantation; 2011 May; 91(9):1010-8. PubMed ID: 21403590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B cell monitoring of transplant patients treated with anti-CD20.
    Abdallah KO; Prak ET
    Clin Transpl; 2006; ():427-37. PubMed ID: 18365400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More on B-cell-depleting induction therapy and acute cellular rejection.
    van den Hoogen MW; Hilbrands LB
    N Engl J Med; 2009 Sep; 361(12):1215; author reply 1215-6. PubMed ID: 19771606
    [No Abstract]   [Full Text] [Related]  

  • 9. Rituximab for humoral rejection after kidney transplantation: an update.
    Rostaing L; Guilbeau-Frugier C; Kamar N
    Transplantation; 2009 Apr; 87(8):1261. PubMed ID: 19384176
    [No Abstract]   [Full Text] [Related]  

  • 10. B-cell-depleting induction therapy and acute cellular rejection.
    Clatworthy MR; Watson CJ; Plotnek G; Bardsley V; Chaudhry AN; Bradley JA; Smith KG
    N Engl J Med; 2009 Jun; 360(25):2683-5. PubMed ID: 19535812
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of rituximab therapy on response to tetanus toxoid vaccination in kidney-transplant patients.
    Puissant-Lubrano B; Rostaing L; Kamar N; Abbal M; Fort M; Blancher A
    Exp Clin Transplant; 2010 Mar; 8(1):19-28. PubMed ID: 20199367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection.
    Mulley WR; Hudson FJ; Tait BD; Skene AM; Dowling JP; Kerr PG; Kanellis J
    Transplantation; 2009 Jan; 87(2):286-9. PubMed ID: 19155986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute interstitial nephritis of plasma cells: a new cause for renal allograft loss.
    David-Neto E; Ribeiro DS; Ianhez LE; Palomino S; Saldanha LB; Arap S; Sabbaga E
    Transplant Proc; 1993 Feb; 25(1 Pt 2):897-9. PubMed ID: 8442259
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of pretransplant antibodies on early renal allograft rejection.
    Alarif L; Rodriguez R; Blackburn S; Light JA
    Transplant Proc; 1987 Feb; 19(1 Pt 1):771-2. PubMed ID: 3274869
    [No Abstract]   [Full Text] [Related]  

  • 15. The clinical application of monoclonal antibody therapies in renal transplantation.
    Dhanireddy KK; Xu H; Mannon RB; Hale DA; Kirk AD
    Expert Opin Emerg Drugs; 2004 May; 9(1):23-37. PubMed ID: 15155134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging role of rituximab in organ transplantation.
    Becker YT; Samaniego-Picota M; Sollinger HW
    Transpl Int; 2006 Aug; 19(8):621-8. PubMed ID: 16827678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4 monoclonal antibodies in the preclinical dog renal allograft model.
    Watson CJ; Davies HS; Metcalfe SM; Cobbold SP; Rebello PR; Collier DS; Waldmann H; Calne RY
    Transplant Proc; 1993 Feb; 25(1 Pt 1):804-6. PubMed ID: 8438491
    [No Abstract]   [Full Text] [Related]  

  • 18. Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients.
    Matignon M; Tagnaouti M; Audard V; Dahan K; Lang P; Grimbert P
    Transplant Proc; 2007 Oct; 39(8):2565-7. PubMed ID: 17954175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
    Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B cells: a rational target in alloantibody-mediated solid organ transplantation rejection.
    Pescovitz MD
    Clin Transplant; 2006; 20(1):48-54. PubMed ID: 16556153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.